NEW AMBRX BIOPHARMA INC (AMAM) Stock Overview
USA - NASDAQ:AMAM - US6418711080 - Common Stock
AMAM Key Statistics, Chart & Performance
The current stock price of AMAM is 28 USD. In the past month the price increased by 0.79%. In the past year, price increased by 188.96%.
AMAM Latest News, Press Relases and Analysis
AMAM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.55 | 403.23B | ||
| AMGN | AMGEN INC | 13.41 | 157.40B | ||
| GILD | GILEAD SCIENCES INC | 15.46 | 148.48B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.82 | 107.82B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.67 | 70.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.34B | ||
| ARGX | ARGENX SE - ADR | 88.73 | 50.31B | ||
| INSM | INSMED INC | N/A | 39.82B | ||
| ONC | BEONE MEDICINES LTD-ADR | 4.99 | 34.01B | ||
| NTRA | NATERA INC | N/A | 26.72B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.45B | ||
| BIIB | BIOGEN INC | 9.48 | 22.26B |
Related stock screener links
About AMAM
Company Profile
Ambrx Biopharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in La Jolla, California and currently employs 66 full-time employees. The company went IPO on 2021-06-18. Ambrx Biopharma Inc. is a clinical-stage biopharmaceutical company. The firm is focused on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. The company is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its ADC targeting Human epidermal growth factor receptor 2 (HER2). The company uses genetic code technology platform to discover and develop engineered precision biologics. Its genetic code technology platform allows to incorporate, in a site-specific manner, synthetic amino acids (SAA), into proteins within living cells. Its SAA incorporation technology is designed to develop a range of product candidate modality, such as modified cytokines and bispecific antibodies, and others.
Company Info
NEW AMBRX BIOPHARMA INC
10975 North Torrey Pines Road
La Jolla CALIFORNIA US
CEO: Feng Tian
Employees: 66
Phone: 18588752400
NEW AMBRX BIOPHARMA INC / AMAM FAQ
What does NEW AMBRX BIOPHARMA INC do?
Ambrx Biopharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in La Jolla, California and currently employs 66 full-time employees. The company went IPO on 2021-06-18. Ambrx Biopharma Inc. is a clinical-stage biopharmaceutical company. The firm is focused on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. The company is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its ADC targeting Human epidermal growth factor receptor 2 (HER2). The company uses genetic code technology platform to discover and develop engineered precision biologics. Its genetic code technology platform allows to incorporate, in a site-specific manner, synthetic amino acids (SAA), into proteins within living cells. Its SAA incorporation technology is designed to develop a range of product candidate modality, such as modified cytokines and bispecific antibodies, and others.
What is the stock price of NEW AMBRX BIOPHARMA INC today?
The current stock price of AMAM is 28 USD. The price increased by 0.07% in the last trading session.
Does AMAM stock pay dividends?
AMAM does not pay a dividend.
What is the ChartMill technical and fundamental rating of AMAM stock?
AMAM has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
How is the valuation of NEW AMBRX BIOPHARMA INC (AMAM) based on its PE ratio?
NEW AMBRX BIOPHARMA INC (AMAM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.57).
Can you provide the market cap for NEW AMBRX BIOPHARMA INC?
NEW AMBRX BIOPHARMA INC (AMAM) has a market capitalization of 12.42B USD. This makes AMAM a Large Cap stock.
AMAM Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to AMAM. When comparing the yearly performance of all stocks, AMAM is one of the better performing stocks in the market, outperforming 98.51% of all stocks.
AMAM Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to AMAM. No worries on liquidiy or solvency for AMAM as it has an excellent financial health rating, but there are worries on the profitability.
AMAM Financial Highlights
Over the last trailing twelve months AMAM reported a non-GAAP Earnings per Share(EPS) of -0.57. The EPS decreased by -16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.43% | ||
| ROE | -34.09% | ||
| Debt/Equity | 0 |
AMAM Forecast & Estimates
14 analysts have analysed AMAM and the average price target is 29.07 USD. This implies a price increase of 3.82% is expected in the next year compared to the current price of 28.
For the next year, analysts expect an EPS growth of -159.66% and a revenue growth -57.14% for AMAM